Back to Research Home
IQVIQVIA Holdings Inc
Health Care · Life Sciences Tools & Services · Large
$279.36+0.37%
As of 23 Oct 2026Mkt cap $43.4B
Stage 13
WAIT
Fundamentals
40.2/75
Technical
4.3/15
Independent
44.5/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +1.6%
- 3M
- +31.0%
- 6M
- +72.1%
- 1Y
- +28.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 34.7xHist median 26.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.2x
- FCF yield
- 4.5%
Quality
- ROIC
- 9.5%
- Operating margin
- 13.4%
- FCF margin
- 12.6%
- Current ratio
- 0.7x
Growth
- Revenue growth
- +5.9%Latest FY YoY
- Revenue CAGR
- +4.1%
- EPS CAGR
- +12.2%
- FCF CAGR
- −2.8%
Capital
- Share-count trend
- −3.5%3Y annualised
- Net debt
- $13.8B5.2x OCF
Annual trend
- CAGR 2021–2025
- +4.1%
- Latest · 2025
- $16B
- YoY
- +5.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded